Nuvelo Announces Completion of Common Stock Offering
08 Marzo 2004 - 6:59PM
PR Newswire (US)
Nuvelo Announces Completion of Common Stock Offering SUNNYVALE,
Calif., March 8 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq:
NUVO; NUVOD) today announced the completion of its public offering
of 5,000,000 shares of common stock and the additionalsale of
750,000 shares pursuant to the exercise of an over-allotment option
granted to the underwriters. Including the sale of these additional
shares, the offering was for 5,750,000 shares of common stock at
$13.00 per share, resulting in total gross proceeds of
approximately $74.8 million. UBS Securities LLC acted as the sole
book-running manager in this offering. CIBC World Markets Corp.,
Needham & Company, Inc. and JMP Securities LLC acted as
co-managers. A shelf registration statement relatingto these
securities was originally filed with the Securities and Exchange
Commission on January 26, 2004 and has since been declared
effective. This press release does not constitute an offer to sell
or the solicitation of an offer to buy any of the securities, nor
shall there be any sale of these securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
jurisdiction. This offering of shares of common stock was made only
by means of a prospectus supplement and accompanying prospectus.
Copies of the prospectus supplement and the accompanying prospectus
can be obtained from UBS Securities LLC, ECMG Syndicate, 299 Park
Avenue, New York, NY 10171. About Nuvelo Nuvelo, Inc. is engaged in
the discovery, development and commercialization of life improving
therapeutics for the treatment of human disease. Nuvelo's lead
product candidate, alfimeprase, is partnered with Amgen and is
currently in two Phase 2 trials in two indications, peripheral
arterial occlusion and catheter occlusion. Additional programs
include cardiovascular product candidates ARC183 and rNAPc2 and
drug discovery focused on antibody targets and secreted proteins.
Informationabout Nuvelo is available at our new Web site at
http://www.nuvelo.com/ or by phoning 408-215-4000. Statements
contained in this press release which are not historical in nature,
are intended to be, and are hereby identified as "forward-looking
statements" for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as "believe," "expect,"
"anticipate," "should," "may," "estimate," "goals," and
"potential," among others. Such statements are based on our
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation,
uncertainties relating to drug discovery, clinical development
processes and the development and commercialization of our
molecular diagnostics technology; changes in relationships with
strategic partners and dependence upon strategic partners for the
performance of critical activities under collaborative agreements;
the impact of competitive products and technological changes;
uncertainties relating to patent protection and regulatory
approval; and uncertainties relating to our ability to obtain
substantial additional funds required for progress in drug
discovery and development. These and other factors are identified
and described in more detail in Nuvelo and Hyseq filings with the
SEC, including without limitation Nuvelo's annual report on Form
10-K and the related Form 10-K/A for the year ended December 31,
2002 and Nuvelo's quarterly report on Form 10-Q for the quarter
ended September 30, 2003. We disclaim any intent or obligation to
update these forward-looking statements. DATASOURCE: Nuvelo, Inc.
CONTACT: Pete Garcia, Sr. VP and Chief Financial Officer,
+1-408-215-4574, or , or Nicole Estrin, Manager of Corporate
Communications & IR, +1-408-215-4572, or , both of Nuvelo, Inc.
Web site: http://www.nuvelo.com/
Copyright